Other grades of this product :
| FG 2216 Basic information |
| Product Name: | FG 2216 | | Synonyms: | FG 2216;FG2216;FG-2216;[[(1-Chloro-4-hydroxyisoquinolin-3-yl)carbonyl]amino]acetic acid;FG 2216 (erythropoietic agent);YM 311;(Z)-2-(((1-CHLORO-4-HYDROXYISOQUINOLIN-3-YL)(HYDROXY)METHYLENE)AMINO)ACETIC ACID;N-[(1-Chloro-4-hydroxy-3-isoquinolinyl)carbonyl]glycine | | CAS: | 223387-75-5 | | MF: | C12H9ClN2O4 | | MW: | 280.66 | | EINECS: | | Product Categories: | Inhibitors | | Mol File: | 223387-75-5.mol |
| FG 2216 Chemical Properties |
| Boiling point | 670.6±55.0 °C(Predicted) | | density | 1.571±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | insoluble in H2O; ≥14.05 mg/mL in DMSO; ≥5.12 mg/mL in EtOH with ultrasonic | | form | powder | | pka | 3.20±0.10(Predicted) | | color | white to beige |
| FG 2216 Usage And Synthesis |
| Description | FG-2216 is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2; IC50 = 3.9 micromolar). It has been shown to reversibly stimulate erythropoietin secretion at 100 μM in vitro and to increase hematocrit, red blood cell count, and hemoglobin levels at 50 mg/kg in mice. | | Uses | FG 2216 is an erythropoietic agent which is orally active prolyl-hydroxylase inhibitor which increases erythropoietin production in end-stage kidney disease. | | Biochem/physiol Actions | BIQ (FG-2216) is an orally available and potent inhibitor of prolyl-hydroxylase (PHD). BIQ induces significant and reversible plasma erythropoietin (EPO) levels in vitro and in hemodialysis patients. | | references | 1. hsieh mm, linde ns, wynter a et al. hif prolyl hydroxylase inhibitionresults in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. blood. 2007 sep 15;110(6):2140-7. |
| FG 2216 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye